Skip to main content
C

Cenra Inc. — Investor Relations & Filings

Ticker · 3716 TW Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-04-02 Director's Dealing
Country TW Taiwan
Listing TW 3716

About Cenra Inc.

https://www.cenra.com/

Cenra Inc. is a diversified healthcare enterprise with a history dating back to 1952. The company operates across a comprehensive value chain encompassing research and development, manufacturing, commercial marketing, and long-term care services. Its extensive portfolio includes active pharmaceutical ingredients (APIs), human pharmaceuticals, animal health products, and consumer health brands such as dietary supplements and personal care items. With a global reach spanning over 60 markets, the organization utilizes nine production bases and more than ten specialized technology platforms to deliver integrated health solutions. Cenra Inc. focuses on high-barrier oncology medications, complex generics, and 505(b)(2) drug developments. By integrating scientific innovation with rigorous operational management, the company provides accessible medical care and health services designed to meet evolving needs across all life stages.

Recent filings

Filing Released Lang Actions
115年4月1日內部人設質解質
Director's Dealing Classification · 1% confidence The table discloses a share pledge by the board chairman’s spouse (an insider) of 2,300,000 shares, filed on the public information observatory. This is a personal securities transaction by a director-related party (insider) rather than a corporate financing, dividend notice, or AGM material. It best fits the “Director’s Dealing” category.
2026-04-02 Chinese
114年度財務比率
Regulatory Filings Classification · 1% confidence The document is a standalone tabulation of financial ratios for multiple fiscal years, with no narrative management discussion, no indication of a full annual or interim report, earnings release, or investor presentation. It appears to be a regulatory disclosure on the public information platform (“公開資訊觀測站”) rather than a structured report like a 10-K, IR, or FS factsheet. This falls under the fallback category for miscellaneous regulatory filings.
2026-03-31 Chinese
114年第4季海外子公司投資
Interim / Quarterly Report Classification · 1% confidence The document is a structured financial table from the Taiwan Stock Exchange's Market Observation Post System (MOPS). It details specific investment information regarding overseas subsidiaries for the 4th quarter of the 114th year (Republic of China calendar). Since it provides substantive financial data (investment balances, equity method recognition, and profit/loss) for a specific reporting period, it qualifies as an Interim/Quarterly Report (IR) component rather than a mere announcement or certification. Q4 2025
2026-03-31 Chinese
114年第4季大陸投資
Regulatory Filings Classification · 1% confidence The document is a Taiwan Market Observation Post System (公開資訊觀測站) disclosure by a listed company, showing detailed quarterly Mainland China investment data (names of investees, capital amounts, remittance, shareholding percentages, profit/loss, approval limits, etc.). It is not a full annual or interim report, nor an earnings release or management presentation. Instead, it is a specific regulatory disclosure mandated by Taiwanese authorities. Therefore it best fits the fallback “Regulatory Filings” category.
2026-03-31 Chinese
114年第4季財務報告書 — 202504_3716_AI3.pdf
Regulatory Filings
2026-03-31 Chinese
114年第4季財務報告書 — 202504_3716_AI1.pdf
Regulatory Filings
2026-03-31 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.